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ABSTRACT 
Liposome encapsulation of interferon was performed to 
investigate its effects on the anticellular properties of 
interferon. 
Purified mouse interferon was incorporated into positively 
charged multilamellar liposomes. The growth response of mouse 
leukemia L1210 cells to liposome encapsulated interferon was 
examined. 
Comparison with free interferon showed no significant 
increase in anticellular activity by liposome encapsulation. 
Cells resistant to the antiviral and anticellular effects of 
free interferon were incubated with liposome encapsulated 
interferon. Significant growth inhibition was demonstrated by 
liposome encapsulated interferon, evident at 24 hours but more 
pronounced at 48 hours. The implications of these results for 
mechanisms of interferon resistance is discussed. 
2-5A, an oligonucleotide believed to be an intracellular 
mediator of interferon activity, is unable to penetrate intact 
plasma membranes. Liposome encapsulated 2-5A was incubated with 
cells to see if intracellular transfer of the oligonucleotide, 
with subsequent growth inhibition, could be achieved. Growth 
inhibition by liposome encapsulated 2-5A was not demonstrated. 
Liposome encapsulation of 2-5A does not effectively introduce the 
oligonucleotide into L1210 cells. 
Future research applications of liposome encapsulated 
interferon are discussed. 
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LIPOSOMES 
Liposomes are microscopic structures consisting of one or 
more concentric lipid bilavers enclosing an equal number of 
aqueous compartments. They have gained enormous popularity as 
models for biological membranes. Liposomes are versatile 
structures which have been investigated from manv perspectives. 
Liposomes have also been used as tools for the investigation of a 
wide variety of biological phenomena, including the molecular 
details of membranes, interactions of biological membranes, 
membrane active compounds (ionophores, anesthetics, etc.), cell 
receptor activity, and antibodv-antigen interactions. 
The ability to encapsulate biologically active agents has 
created an exciting area of research. The use of liposomes as 
carriers of biologically active materials has given them a 
significant role in pharmacology. 
PREPARATION 
Liposomes are surprisingly simple to prepare. Dried films 
of phospholipids, alone or mixed with other lipid soluble 
compounds, are shaken with aqueous media. This results in a 
milky colored preparation of multilamel1ar vesicles (MLV) of 
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These structures, originally referred to as heterogeneous size. 
"myelin figures", are composed of concentric lamellae. Each 
lamella consists of a lipid bilaver (Bangham, 1968, Bangham, 
1972, Bangham, etal, 1974) separated from adjacent bilayers by 
aqueous spaces. 
U1trasonica t ion o f these multilamellar 1iposomes tr ans f o rms 
them into much smaller unilamell ar liposomes , cons i s ting of a 
sing le lipid bil ayer . These soni cated unilam ellar v es icles (S UV) 
are more homog eneo us in size. and their tr ans fo rmatio n is 
he r a lded by cle aring o f the orig inal vesicle pr epa r a t ion . The 
1 im i ting size o f these vesicles is approxima telv 200 angst roms, 
def i ned by the c onstrai nt of the small radius of cur va ture o n the 
pack ing of lipid molecules within the vesicle membra ne • 
Lipo somes can be fracti onated acco rd ing to size by 
cent rifugation o r molec ular sieve chromatog ra phv. 
Other methods ha ve been de scribed for the pr eparatio n of 
1 ipo somes of dif fer ing structure. (Batzri and Korn, 1973, Sz oka 
and Papahadjopoulos, 1978, Deamer and Bangham, 1976) 
COM POSITION 
The unique amphipathic properties of phospholipids make them 
an obligatory component of the lipid bilavers of liposomes. 
A variety of other lipids or lipid soluble compounds can be 
incorporated into the bilaver, which enables investigators to 
3 
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change the physical properties of the liposome. 
Most laboratories employ a basic mixture of phospholipid, 
cholesterol, and a charged amphiphile in varying molecular ratios 
(6:3:1 to 5:5:0.5). Changes in liposome composition provide an 
useful variable in liposome investigation, especially in studies 
of liposome- cell interaction. 
Cholesterol is an important component of liposome membranes. 
It increases bilaver stability and reduces leakage of entrapped 
materials (Papahadjopoulos, etal , 1973). 
Liposomes are often given a net surface charge by including 
charged amphiphiles as components of the bilaver. Commonly used 
amphiphiles include stearylamine (positive) and dicetvl phosphate 
(negative). Inclusion of these charged species on the liposome 
surface increases the aqueous space volume within the liposome, 
allowing greater amounts of material to be entrapped. 
The choice of charged amphiphile depends on the material to 
be encapsulated. If the material is not charged, either positive 
or negative amphiphiles can be used. If the material does bear a 
charge, then two schools of thought exist. 
Using an amphiphile of similar charge will minimize 
electrostatic binding of entrapped material to the lipid bilaver. 
Such binding could theoretically decrease the pharmacologic 
activity of the encapsulated drug. 
The use of a charge opposite that of the entrapped species 
also has several utilities. The amount of soluble material 
encapsulated is markedly enhanced. Absorption to both internal 
4 
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and external surfaces can occur, as demonstrated with cytochrome 
C (Kimelberg, etal , 1970). This is especially useful if exposure 
of the material to the external medium is acceptable. If such 
exposure is not acceptable, material associated with the external 
surface can be removed by washing, or treatment with enzymes or 
high ionic strength. 
Papahadjopoulos (1974) has shown that cyclic AMP and 
actinomycin D (1976) could both be encapsulated in oppositely 
charged vesicles without a substantial decrease in pharmacologic 
activity. 
The presence of charged amphiphiles exerts an important 
influence on the mechanism of incorporation into cells. 
FLUIDITY OF LIPID MEMBRANES 
An important physical property of liposomes is the fluidity 
of the lipid bilaver. Phospholipid species undergo a first-order 
thermal phase transition from a solid to a liquid crystalline 
phase at a characteristic temperature. This transition 
temperature (Tc) differs for individual phospholipid species. 
Below the Tc the lipids are in a solid-like state, with their 
hvdrocarbon chains relativelv ordered. Above the T the chains 
c 
are more disordered, with greater freedom of motion, and are 
considered to be in a fluid state. Bilayers in a fluid state 
have decreased thickness. 
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The characteristic T for ea 
c 
defined by its molecular structure. 
decreased chain length, by unsatura 
side groups (e.g. cyclopropane ring 
chains. A characteristic T for 
c 
possible to construct vesicles that 
the required experimental temperat 
liposomal properties has value in 
specific intracellular sites. Choi 
their T decreases fluidity, 
c 
permeability (Poste, etal , 1976). 
ch phosphol ipid species is 
In general , T i 
c 
s lowered bv 
tio n of acyl cha i ns, by bul kv 
s) , and by br anc hing of ac yl 
eac h phosph ol ipi d makes it 
ar e either sol id or fluid at 
ur e . Such man i pulation of 
ta rgeting of 1 ipo somes to 
est erol added to lipids above 
c oncomitan tly decreasi ng 
PERMEABILITY 
Liposome permeability has been studied by several methods, 
including efflux of radiolabeled material, efflux of non¬ 
rad iolabel led materials (where appropriate assavs exist), changes 
in optical density of liposome suspensions, and changing 
osmolaritv of the external aqueous environment. 
Liposomes composed of unmodified phospholipids are extremely 
impermeable to cations (Na+, K+), but are generally more 
permeable to anions (Cl ) (Bangham, etal, 1965) The ions fluxes 
are considered quite low compared with most natural membranes. 
Liposomes show considerable permeability to water, comparable to 
natural membranes. 
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The effects of protein on liposome permeability are 
important to understand. The presence of proteins is the 
principle difference between liposomes and natural membranes. 
Plasma proteins, present both in both in vitro and in vivo 
systems, are rapidly absorbed by liposomes (Black and 
Gregoriadis, 1976). 
Binding of proteins to liposomes may increase permeability 
to encapsulated materials (Kimelberg and Papahadjopoulos, 1971). 
Cell culture media are full of serum components and released 
cellular proteins, which may become a more significant problem 
with long incubations. Liposomes also confront this problem in 
vivo; body fluids are full of proteins capable of interacting 
with liposomes and increasing their permeability. 
The inclusion of cholesterol in the liposome bilayer will 
substantially reduce the permeability to entrapped materials, 
even in the presence of protein (Papahadjopoulos, etal, 1973). 
INTERACTION WITH CELLS IN VITRO 
Cultured mammalian cells show a great affinity for 
liposomes. Incorporation of up to one million liposomes per cell 
has been demonstrated without effect on cell viability or growth 
rates. A variety of cell types can incorporate liposomes of 
widely varying lipid compositions without cytotoxic effects. 
Different cells exhibit similar kinetics of liposome uptake. 
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At 37' C there is rapid uptake of liposomes within the first two 
hours, which levels off, reaching a plateau after 3-8 hours 
(Poste, etal , 1976). 
Mechanisms of liposome-cell interaction include stable 
adsorption, endocvtosis, fusion, and lipid exchange. Vesicle 
surface charge and the physical state of the vesicle lipids are 
important determinants of the mechanism of vesicle incorporation 
(Poste and Papahadjopoulos, 1975) 
Stable adsorption implies association of liposomes with the 
cell surface, remaining intact on the surface without 
internalization. Scanning electron microscopy of fibroblasts 
incubated with liposomes demonstrates a characteristic bumpy 
surface, wheareas untreated cells have a smooth surface (Pagano 
and Takeichi, 1977). The diameter of the bumps ranges from 300- 
1000 angstroms, consistent with adsorption of vesicles to the 
cell surface. While repeated washings do not remove adsorbed 
liposomes from the cell surface, trypsin can remove them, 
suggesting an important role for cell surface proteins in this 
interaction. 
Endocvtosis is traditionally classified as pinocytosis 
(uptake of fluid) or phagocytosis (uptake of particles). Either 
of these processes can theoretically mediate cellular uptake of 
liposomes. Evidence for endocvtosis of liposomes is abundant. 
Papahadjopoulos (1974) demonstrated that radiolabelled 
unilamellar vesicles with a different radiolabelled component 
trapped inside the vesicle are taken up as intact structures. 
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Liposome components have been demonstrated within cells by 
electron histochemistry (Magee, etal , 1974) and electron 
radioautography (Huang and Pagano, 1975). Liposomes have been 
found in lysosomes (Gregoriadis, etal, 1971). Endocvtosis was 
reduced in fibroblasts bv cvtochalasin B or appropriate metabolic 
inhibitors of respiration or glycolysis. 
The appearance of liposome contents in the cytoplasm is the 
strongest evidence supporting the mechanism of liposome-cell 
fusion. The presence of such material in the cytoplasm has been 
established by many investigators. Tissue cells were incubated 
with liposomes containing cyclic AMP (Papahadjopoulos, etal, 
1974) and actinomycin D (Poste and Papahadjopoulos, 1976) and 
biological activity of these compounds indicated their presence 
in the cytoplasm. Lymphocytes incubated with liposomes 
3 
containing H-inulin showed random distribution of the 
radiolabeled marker throughout the cytoplasm (Huang, etal, 1978). 
Evidence for fusion has also been provided by studies employing 
ultrastructural histochemistry (Weissman, etal, 1977) and 
fluoresence microscopy (Weinstein, etal, 1977). 
Exchange of rad iolabel1ed phospholipids has been observed 
between various cell and liposome types (Huang, etal, 1978) 
Rad iolabelled phospholipids moved from vesicles to cells, and 
vice versa. The molecular mechanism of this exchange is yet 
undetermined, but involves interaction of the lipids of the outer 
liposome monolayer and the cell surface. Lipid monomers may be 
transferred, with possible mediation by lipid exchange proteins 
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Intermediate present in the cell surface or in the medium, 
structures may also be formed, with transient, reversible merging 
of the outer monolayers of liposomes and cell plasma membranes 
Lipid exchange is probably not responsible for significant 
incorporation of vesicle of lipid into cells at 37' C, but may 
predominate at low temperatures (Pagano and Huang, 1975). 
LIPOSOME IMMUNOLOGY 
Immune responses to liposomes are important to understand 
and minimize for optimal in vitro and in vivo use of liposomes. 
Complement can mediate lysis of liposomes. Immune damage of 
liposomes involves the same classical complement sequence 
responsible for the antibody-induced lysis of cells (Haxby, etal, 
1969). Cunningham (1979) found that liposomes can also activate 
the alternative pathway of human complement. A positive surface 
charge on the liposome was required for C^ conversion. 
Activation was also influenced by liposomal cholesterol 
concentration, phospholipid fatty acyl chain length, and degree 
of saturation, all suggesting membrane fluidity as an important 
determinant of complement fixation. Thoughtful liposome design 
can thus minimize complement-mediated lysis of liposomes, which 
would adversely affect their carrier function. Heat-inactivat ion 
of serum used with liposomes has also been advocated, since heat- 
inactivation presumably destroys complement factors. 
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The ability of liposomes to induce humoral or cell-mediated 
immunity is of great interest because of their potential as 
carriers of biologically active agents in vivo. 
One theoretical advantage of liposome entrapment of 
potentially immunogenic substances (e.g. foreign proteins) is 
prevention of antibody formation, which could inactivate the 
substances. Though theoretically attractive, full prevention of 
immunogenicitv of entrapped substances has not fully 
materialized. Allison and Gregoriadis found that mice produced 
more antibodies against diphtheria toxoid when immunized with the 
antigen encapsulated in negatively charged liposomes. (Allison 
and Gregoriadis, 1974). However, they also showed a marked 
decrease in allergic reaction (i.e. Arthus reaction, serum 
sickness) when animals were subsequently challenged with liposome 
encapsulated diphtheria toxoid (Gregoriadis and Allison, 1974). 
The incorporation of any drug or protein into liposomes 
increases the risk of immunogenicitv. Immune responses to 
purified naturally occuring lipids are not significant, and 
liposomes composed solely of these substances would have minimal 
immunogenicitv (Rapport and Graf, 1969). 
11 
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DISTRIBUTION AND INTERACTIONS OF LIPOSOMES IN VIVO 
The in vivo interactions of liposomes are important to 
understand for guiding in vivo research and developing clinical 
applications of liposome technology. The fate of liposomes 
varies with their route of administration. 
Liposomes injected intravenously interact with a variety of 
substances. Serum proteins, lipoproteins, and other plasma 
components are encountered. Binding to erythrocytes has been 
documented (Kimelberg, 1976), and binding to leukocytes and 
platelets probably occurs. 
The ability of liposomes to reach target tissue cells 
depends on their ability to cross capillaries into the tissues. 
Intact liposomes can pass from capillary lumen to interstitial 
space by endocvtosis by endothelial cells, or by passage through 
intercellular spaces. However, even the smallest liposome could 
be too large for passage by these mechanisms. Fusion of 
liposomes with endothelial cells would allow liposomal contents 
to traverse the cell and emerge in the interstitial space. 
Distribution studies of radiolabelled liposomes show they 
are cleared from blood and taken up by tissues after intravenous 
injection. Both composition and size affect the rate of 
clearance. Larger liposomes are cleared more rapidly than 
smaller ones (Kimelberg, 1976). Liposomes negatively charged 
before injection are cleared more rapidly than positively charged 
or neutral ones (Kimelberg, 1976, Juliano and Stamp, 1975). 
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Black and Gregoriadis (1976) demonstrated that in the presence of 
serum, all liposomes acquire a negative charge. Therefore, 
differences in interaction with blood proteins or differences in 
final net negative charge density could be responsible for the 
differential clearance rates observed between liposomes with 
different charges before injection. 
The liver takes up the largest amount of an intravenous dose 
of liposomes. Its large size and blood supply, as well as a high 
specific uptake by the reticuloendothelial system, are probably 
responsible for this. Up to 50% or more of labelled lipid or 
liposomal contents can be present in the liver within hours after 
administration (Gregoriadis, 1973). 
Other tissues take up liposomes (Gregoriadis, 1973, 
Kimelberg, etal, 1976) with kidney, lung, and spleen taking up 
significant amounts. Gastrointestinal tissues do not take up 
liposomes very strongly. 
Liposomes taken up by the liver can be found within both 
hepatocytes and Kupffer cells, suggesting endocvtosis as the 
method of uptake by liver. Liposomes have also been found in 
lvsosomes, as demonstrated by fractionation studies (Gregoriadis 
and Rvman, 1972, Segal, etal, 1976). 
Intraperitoneal administration of liposomes shows similar 
tissue distribution, with liver, spleen, lung, and kidney as 
major sites of tissue uptake. Intestinal uptake of 
intraperitoneallv injected liposomes is also low. Distribution 
is generally more even, with diminished liver and plasma levels 
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and 
compared to intravenous injection. 
Many drugs are ineffective when administered orally, 
liposome encapsulation has allowed such drugs to show activity. 
Intragastric administration of liposome encapsulated insulin 
resulted in marked decreases in blood glucose levels in diabetic 
and normal rats (Patel and Ryman, 1977) compared to free insulin 
and empty liposomes. Similar effects were seen with liposome 
encapsulated glucose oxidase. Liposome encapsulation protected 
these substances from inactivation in the gut and facilitated 
absorption into the bloodstream. This technique offers great 
practical advantages to allow oral administration of otherwise 
ineffective agents. 
CARRIER POTENTIAL OF LIPOSOMES 
The use of liposomes as carriers to introduce biologically 
active materials to cells was first demonstrated by Magee and 
Miller (1972). Treatment of mouse L cells with multilamellar 
vesicles containing IgG with a high neutralizing titer to 
Coxsackie virus A-21 protected the cells against subsequent 
infection by that virus. The IgG-containing liposomes were 3000- 
10,000 times more effective in protecting cells than the 
equivalent titer of free antibody. 
The use of liposomes for introducing material directly into 
the intracellular environment was demonstrated by Gregoriadis and 
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Buckland (1973), who used liposomes to introduce invertase into 
invertase-deficient mouse macrophages and human fibroblasts. 
Since these pioneering experiments, a staggering array of 
substances have been encapsulated in liposomes for delivery to 
cells, including hormones, enzymes, plasma proteins, antibiotics, 
lvmphokines, bacterial products, immunoglobulins, nucleotides, 
polynucleotides, steroids, chemotherapeutic agents, vitamins, 
chelating agents, and viruses (Gregoriad is, 1976). 
Advances in liposome technology have made possible 
construction of different types of liposomes with diverse 
physical properties. Investigators have thus been able to modify 
liposomes to meet a variety of experimental demands. The ability 
to construct vesicles over a wide size range (200 A to 10 urn) 
enables materials of widely differing molecular weights to be 
incorporated into liposomes. 
Gregoriadis (1977) has reviewed approaches for targeting 
drugs. A variety of materials have been employed as carriers of 
drugs, and liposomes have many properties which make them the 
most promising of carriers. An ideal carrier should be non¬ 
toxic, biodegradable, and physically versatile enough to 
accomodate a variety of drugs. It should be stable, protecting 
its contents from the external environment (and vice versa), with 
the ability to cross cellular and anatomic barriers. Liposomes 
fulfill these criteria, and have demonstrated ability to function 
as effective carriers of biologically active materials. 
15 
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TARGETING OF LIPOSOMES 
Specificity is an important quality for successful 
application of pharmacologically active agents. Pharmacologists 
have traditionally improved specificity of drugs through creation 
and fashioning of molecular structure. The use of liposomes as 
versatile carriers of drugs introduces an exciting alternative 
approach to the problem of drug specificity. The specificity of 
the liposome carrier itself can be altered. 
Investigators have taken several approaches to improve the 
specificity of liposomes. Targeting of liposomes to specific 
regions of the cell has been attempted by influencing the mode of 
liposome-cell interaction. Liposomes designed to be incorporated 
by endocytosis can deliver their contents to lvsosomes. While the 
phospholipid surface of liposomes is not a strong endocvtic 
stimulus into the lysosomal system (deDuve, 1969), aggregated 
immunoglobulins constitute a strong stimulus for such 
endocytosis. Vesicles designed to enhance fusion with cellular 
membranes will deliver a greater proportion of their contents to 
the cytoplasm. 
Altering liposome specificity for target tissue has also 
been studied. In vivo studies show the majority of intravenously 
introduced liposomes are taken up nonspecificallv by fixed 
macrophages of the reticuloendothelial system (Gregoriadis, 
1973). This clearly hinders effective delivery of drugs not 
destined for the RES system. However, this pattern of 
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distribution can be modified. 
Varying the size and charge of liposomes affects their in 
vivo behavior. Changes in lipid composition also alters their 
tissue distribution. 
Sonication of liposomes can affect tissue distribution. 
Using negatively charged liposomes containing radiolabelled 
bleomycin, Gregoriadis and coworkers (1977) demonstrated that 
increasing sonication time not only decreased uptake by liver and 
spleen, but also increased uptake by solid and ascitic tumors. 
Pretreatment of animals with large doses of empty liposomes 
can effectively reduce RES uptake of subsequently administered 
liposomes (Haynes and Kang, 1978). The empty liposomes 
temporarily saturate the reticuloendothelial system, leaving it 
with diminished capacity to take up subsequent doses of 
1iposomes. 
A more versatile approach for increasing liposome 
specificity uses molecules inserted at the liposomal surface, 
which can bind liposomes selectively to appropriate cells. A 
variety of ligands have been associated with liposomes, attached 
by nonspecific forces or by one of the ligand's binding sites. 
These ligands can interact with specific determinants on the 
surfaces of cells, making the liposomes more selective in their 
cellular interactions. 
Immunoglobulins offer the most refined targeting potential 
for liposomes. By attaching IgG immunoglobulin to liposomes 
through their F portion, the F , moietv extends into the 
C 3D 
17 

external environment, and can theoretically recognize and 
associate with the respective antigens on the target cell 
surface. Immunoglobulins raised against a particular antigen 
could be incorporated onto the liposomal surface, rendering those 
liposomes selective for a specific target. The potential targets 
would be limited only by the ability to raise antibodies against 
them . 
Immunoglobulin-coated liposomes have been used to introduce 
enzymes into deficient cells. Weissman and coworkers have 
used this method to introduce purified hexosaminidase A into Tay- 
Sachs leukocytes (Cohen, etal, 1976). Horseradish peroxidase has 
been introduced by immunoglobulin-coated liposomes into smooth 
dogfish phagocytes, which lack endogenous peroxidase in their 
lvsosomes (Weissman, etal, 1975). These experiments demonstrate 
the potential use of liposomes to deliver enzymes to cells of 
patients with deficiency diseases. 
Cell specificity of liposomes was demonstrated by raising 
IgG against whole HeLa cells (Gregoriadis and Neerunjun, 1975) 
111 i2S 
Liposomes containing In-labelled bleomycin had I-labelled 
anti-HeLa IgG attached to their surface. These liposomes were 
incubated with both HeLa cells and human skin fibroblasts. The 
uptake of both bleomycin and IgG radioactivity by HeLa cells was 
25 times greater than uptake by fibroblasts. When the same 
liposomes had labelled anti-fibroblast IgG on their surfaces 
instead, the uptake of both radioactivities by fibroblasts was 
five-fold greater than in HeLa cells. Both cell types shared 
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similar rates of uptake when incubated with liposomes bearing 
nonspecific IgG. 
Heath and coworkers (1980) 
specificity through antibody targ 
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a 200- fold increase in bindi ng of v esic 
wh en compared to controls. 80% of V 
we re a ssoc iated with the cel Is. 
Cell-: specif ic IgG on the 1 ipo 
se lect ive uptake of both c arr ier and 
ra i sed ag < ainst wh ole cell s effec t i ve 
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INTERFERON 
Inter fer 
Lindenmann (I 
influenza vir 
in London, 
inter ference, 
virus seemed 
virus. 
on was discovered in 1957 by Alick Isaacs 
saacs and Lindenmann, 1957a, 1957b). Inve 
uses at the National Institute for Medical 
Isaacs and Lindenmann were both interested 
a phenomenon in which infection by one 
to inhibit subsequent infection by other 
and Je an 
st igati ng 
Resear ch 
in vir al 
type of 
types o f 
They incubated chick chorioallantoic membrane with heat- 
inactivated influenza virus. The cells resisted further 
infection by other viruses added to the culture. Supernatants 
from these cultures were able to protect fresh cultures of 
membrane from infection by live virus. 
The substance confering protection against further viral 
infection, presumed responsible for the 'viral interference' 
observed, was named interferon. 
Since this d isco very, muc h has been learned about 
inter fe ron. Though or ig i nal iy de sc r i bed as an ant iv i ral 
substance, many othe r pr ope r t i es hav e been at t r ibuted to 
inter fe ron, includ ing anti pro lif era t i ve and immuno reg ula tory 
prope rties. 
Early inter fer on resea rch wa s c ompl icated by the rel a t ive 
impur ity of availabl e in ter fe ron pr epa rati ons. However , prog ress 
in interferon pu r i f i ca t io n tec hn i ques has pe rm i tted the 
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production of interferon of extremely high purity. 
Human interferon is very expensive and difficult to obtain. 
The major source of human interferon has been Dr. Kari Cantell of 
the Central Public Health Laboratory in Helsinki, Finland. Large 
scale production of human interferon by recombinant DNA 
techniques would be a great advance for interferon research. 
CLASSIFICATION OF INTERFERONS 
At least three types of interferon with different antigenic 
specificities have been described. Thus, rather than a single 
substance, the interferons represent a family of glycoproteins. 
Type I, or classical interferon, is the same type discovered 
by Isaacs and Lindenmann. It can be produced by a wide variety 
of cell types, with production induced by a wide variety of 
agents, both viral and non-viral (Ho and Armstrong, 1975). The 
newest interferon classification svstem recognizes the classical 
interferons independant1y as alpha interferon (leukocyte 
interferon) and beta interferon (fibroblast interferon). Human 
lymphoblastic interferon is a mixture of alpha (leukocyte) and 
beta (fibroblast) interferons, with beta interferon predominant. 
In 1965, Wheelock stimulated human leukocyte cultures with 
phvtohemagglutin (PHA) and found that the supernatant contained 
an antiviral, interferon-like substance (Wheelock, 1965). This 
has since been called gamma, type II or immune interferon. Gamma 
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PRODUCTION OF INTERFERON 
Induction of classical interferon (alpha and beta 
interferons) can be accomplished by a wide variety of agents. 
including intracellular microo rganisms. bacter ial produc ts, 
polymers, and many low molec ular weight substances (Ho and 
Armstrong , 1975) . Grossberg (1979) has developed a modified 
classification of interferon inducers. 
Class A inducers are relatively potent and contain nucleic 
acid. These include RNA and DNA animal viruses, plant and insect 
viruses, mvcophages and bacteriophages, double stranded RNA from 
normal cells, and synthetic double stranded RNA. 
Class B inducers are relatively weak compared with Class A 
inducers, and include intracellular microbes (e.g. Bordetella, 
Brucella, Franciscel1 a, Hemophilus, Listeria, and Serratia), 
rickettsia, chlamydia, mycoplasma, and protozoa. Certain 
microbial products, such as 1ipopolysaccharides, as well as 
certain polymeric chemicals and various low molecular weight 
substances also induce interferon. 
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Certain human tumor lines (colorectal carcinoma, melanoma, 
rhabdomyosarcoma, and cervical carcinoma) interestingly induce 
interferon production by allogeneic human lymphocytes. The 
interferon produced has the phvsical properties of type I 
interferon (Trinchieri, etal , 1977). 
Gamma, or immune interferon, is produced by the lymphocyte. 
Both human T and B lymphocytes can produce interferon in vitro in 
response to the mitogens PHA and PWM (Epstein, etal, 1974). 
Interferon production by lymphocytes is markedly enhanced in the 
presence of macrophages. This enhancement is probably related to 
macrophage presentation of mitogen or antigen to the lymphocytes. 
Inducers of gamma interferon generally induce relatively low 
levels of interferon. The immune status of the lymphocyte donor 
is an important factor. Immune interferon inducers comprise 
those exerting nonspecific mitogenic effects, and those showing 
an immune specific antigenic effect on the cells to be induced. 
Mitogens able to induce gamma interferon production include 
phvtohemagglutinin (PHA), pokeweed mitogen (PWM), concanavalin A 
(ConA), streptolysin 0 (SLO), and staphylococcal enterotoxin A 
(SEA). Antilymphocyte serum (ALS) and Corvnvbacteriurn parvum can 
also induce gamma interferon. 
Antigens capable of inducing gamma interferon in sensitized 
lymphocytes in vitro include bacterial antigens, purified protein 
derivative (PPD), tetanus toxoid, and diphtheria toxoid. Viral 
antigens from vaccinia, herpes simplex, and varicella zoster are 
also able to induce immune interferon. 
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In additi Lon to herpes simplex ant igen , herpes sim plex virus- 
ant ibody complexe s can st imul ate in terferon production 
(Fu j i b a va shi , etal , 1975) . Thus, i nte r fero n may st ill be induced 
in sensit i zed cells , even if viral an t igen ic sites ar e masked by 
ant ibody. 
GENETICS 
Interferon sensitivity is dependent on human chromosome 21. 
Tan (1973), studied mouse-human hybrids, and found that the 
presence of human chromosome 21 enabled the hybrids to respond to 
the antiviral effects of human interferon. If human chromosome 21 
was lost from the hybrid, the response to interferon was also 
lost. 
The response to interferon var ie s in cell s containi 
different numbers of chromosome 21. Cel 1 s from humans wi 
trisomy 21 are more responsive to exogeno us interfer on than cel 
from normal individuals, and cells monosomic for chromosome 21 
are less responsive (Tan, etal , 1974, Chany, 1975, DeClercq, 
eta 1 , 1975) 
The gene responsible for expression of antiviral effects of 
interferon (AVG) was localized to the distal portion of the long 
arm of chromosome 21 by Epstein and Epstein (1976). Normal 
fibroblasts and fibroblasts monosomic and trisomic for chromosome 
21 were incubated with interferon. Cells with trisomy 21 
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demon strated an antivira 1 ef f ect three times that of no rmal 
cell s . Monosom ic cells h ad an antiviral response one-fifth tha t 
of no rmal cells. A cell 1 ine t risomic only for the dista 1 half 
of the long arm of chromosome 21 permitted the more precise 
local ization of AVG. 
Interferon prod uc tio n i s d etermined by huma n chromo some 5 
(Tan , 1977) , as shown by studie s on human-Chinese hamster hybrid 
popul at ions. 
Leukocyte and fibrobl ast in terferon share many ' simila r i t ies. 
They are both gl ycoprotein s wi th similar molecula r we ights • They 
both show immuno modulatory act iv itv, can activate natural ki Her 
cells , have promising an tivira 1 and antitumor ac tivitie s, and 
are suf ficientl y similar to be recognized by th e same r ece ptor 
(Pauc ke r, 1977) . Their svnthe ses appear to be under sim ilar 
con tr ol. Howev er, sever al dif ferences suggest they are enc oded 
for by differ ent genes , including differen t target cell 
spec i ficities, different dose -response curves fo r an t iv iral 
ac t i v itv, and different degrees of growth inh ib ii tory act ion. 
Antibodies dir ected ag a inst leukocyte inter f e ron do not 
neut r alize fibro blast inte r feron , and vice versa. 
Nucleotide and amino ac id analysis of the c lo ned genes of 
human leukocyte interfere n and human fibroblast in ter fero n show 
signi ficant homo logies (Ta n ig uch i, etal , 1980 ) . Homologv between 
these two genes wa s 45 % a t the nucleotide level an d 29% at the 
am ino acid leve 1, strong ly suggesting derivatio n from a common 
ancestral gene. 
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Recombinant DNA technology has permitted cloning of the 
human fibroblast interferon gene. (Derynck, etal, 1980) 
Isolation and sequencing of the gene has allowed the amino acid 
sequence to be deduced. The protein contains 166 amino acids and 
is preceded by a 21 amino acid signal sequence. As interferon is 
a secretory protein, this sequence probably represents a signal 
peptide, cleaved off as or after the nascent protein crosses the 
endoplasmic reticulum. While mature fibroblast interferon is a 
glycoprotein, precise description of the carbohydrate moieties on 
the polypeptide has not been achieved. 
SPECIES SPECIFICITY 
An interesting aspect of interferon biology is its species 
specificity. Though species specificity exists to a relatively 
high degree, it is not complete. For instance, one form of human 
leukocyte interferon is equally active on human and rabbit cells 
(Stewart and Desmyter, 1975). 
Some components of the interferon system are not species 
specific. Cells rendered resistant to viral infection by 
homologous interferon can transfer resistance to heterologous 
cells insensitive to that interferon. Blalock and Baron (1977) 
cocultivated human amnion and baby hamster kidney cells with 
mouse L cells in the presence or absence of mouse interferon. 
When challenged with vesicular stomatitis virus (VSV), transfer 
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of viral resistance to the human and hamster cells was observed, 
presumably by a product of the interferon treated mouse cells. 
Transfer of viral resistance was also observed between cells 
of the same species. Interferon treated L cells were washed free 
of interferon, then treated with excess antiserum to mouse 
interferon. Untreated L cells were added , and viral resistance 
was transferred to the newly added, untreated cells. (Blalock 
and Baron , 1977 ) . 
Isolation of the factor(s) responsible for this 
intercellular transfer of viral resistance will be an important 
step in understanding amplification of the interferon system. 
Bourgeade (1974) examined the role of cell membrane 
receptors in the species specificity of interferon. Receptors 
for monkey and mouse interferon are distinct in somatic monkey- 
mouse hybrid cells. The two types of receptors exhibited 
differential sensitivitv to trypsin. Bv examining the antiviral 
response of the hybrid cells to both monkey and mouse interferon, 
Bourgeade concludes that only the interferon membrane receptors 
govern the cell species specificity of the different biological 
effects of interferon. 
Carter (1979) examined the species specificity of 
interferon, and found carbohydrate-altered leukocyte interferon 
could exert effects on heterologous cells. Porcine and bovine 
carbohvdrate-altered interferons from leukocytes demonstrated 
increased efficacy in protecting human cells from viral 
challenge. Carter proposes that, as a glycoprotein, interferon's 
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ability to cross or not cross species lines lies in the 
carbohydrate moiety, and cross species biological activity is a 
property of the polypeptide. If Carter's theory is correct, 
carbohydrate-altered animal interferons could conceivably be 
effective in experimental systems using human cells. This would 
be a tremendously useful contribution to interferon research. 
ASSAY OF INTERFERON 
Interferon has a very high specific activity, greater than 
one billion units per milligram of protein. One unit of 
interferon is defined as equal to the amount required to reduce 
viral yield by 50%. 
The assay methods used to measure interferon's antiviral 
activity are many, and have been reviewed by Grossberg (1979). 
Thev can be summarized as 1) inhibition of generalized cell 
specific cvtopathic effects in a monolaver of cells, 2) 
reduction in the number and size of viral plaques, 3) reduction 
in vield of either infectious virus or viral hemagglutinin, 4) 
reduction in yield of a virion-associated structural enzyme, 5) 
reduction in quantitative hemadsorption, 6) changes in relative 
cellular metabolism, 7) activity of cells surviving virus- 
induced cytolvsis to take up a vital dye, and 8) inhibition of 
RNA synthesis. 
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ANTIVIRAL ACTIVITY 
Interferon plays an important role in recovery from viral 
infections. Interferon appears early in the course of a viral 
infection, with rapidly rising titers within 24 hours of 
infection. Interferon limits viral replication at the portal of 
entry, reduces viremia and subsequent dissemination, and protects 
target organs against infection. Its appearance preceeds 
formation of antibodies. This has been demonstrated by numerous 
studies in both animals and man (Baron, 1973). 
Anti-interferon antibodies have been employed to examine the 
extent to which interferon plays a role in fighting viral 
infection. When anti-interferon antibodies were injected 
simultaneously with virus, death occurred earlier than in animals 
injected with virus alone (Fauconnier, 1970). Virus-infected 
mice treated with sheep anti-mouse interferon serum demonstrated 
severlv limited ability to fight the infection (Gresser, etal , 
1976a). Higher titers of virus were found in visceral organs, 
onset of disease was accelerated, and death occurred earlier in 
animals receiving the anti-serum. 
Other evidence dramatically illustrates the importance of 
interferon in combating viral infection (Gresser, etal, 1976b). 
Mice were given herpes simplex virus (HSV) type I subcutaneously. 
Anti-mouse interferon globulin treatment resulted in death in all 
mice. Only 5% of the virus-infected control mice died. 
Virus-induced tumors are also affected bv interferon 
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(Gresser, 1977). In mice treated with anti-interferon globulin, 
MSV-induced tumors appeared earlier, in a greater proportion of 
mice, and were larger in size (Gresser, etal, 1976b). The 
development of Friend leukemia is inhibited by interferon 
(Gresser, etal, 1967). Interferon treatment also decreased the 
incidence of lymphoid leukemia and significantly increased the 
survival time of AKR mice, who develop spontaneous virus-induced 
leukemia (Gresser, etal, 1969b). Interferon plays an important 
role in the prevention of virus-induced tumors. 
ANTICELLULAR ACTIVITY 
The anticellular effect of interferon has been established 
by many investigators, and has attracted several explanations. 
The inhibition of cell growth by interferon could result from 1) 
inhibition of tumor virus replication and reduction of viral cell 
transformation, 2) direct inhibitory effects of interferon on 
cell growth, 3) growth inhibition mediated by interferon-induced 
changes in the immune system, or a combination of these effects 
(Friedman , 1978) . 
The first evidence of interferon anticellular activity was 
gathered bv Paucker, Cantell, and Henle (1962), who found that 
crude interferon preparations inhibited the multiplication of 
mouse L cells in suspension cultures. 
The growth of several transplantable tumors in mice was 
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inhibited by repeated injections of interferon preparations 
(Gresser, etal, 1969a, 1970a). Interferon-treated mice had 
increased survival, and were often without obvious sign of tumor. 
Interferon treatment of mouse leukemia L1210 cells in vitro 
significantly decreased their subsequent oncogenicity in DBA/2 
mice and their colony forming capacity in agarose (Gresser, etal, 
1971a). 
Interferon preparations can also inhibit the growth of 
normal cells. Lindahl-Magnusson (1971) showed that interferon 
inhibited the growth of mouse embryo and weanling mouse kidney 
cells. Interferon inhibited the regeneration of the liver in 
partially hepatectomized mice (Frayssinet, etal, 1973). Newborn 
mice treated with interferon exhibited weight loss and diffise 
hepatic cell degeneration (Gresser, etal, 1975). Drasner and 
coworkers (1971) studied the antiproliferative effects of 
interferon on mouse embryo development, and found responsiveness 
to interferon was achieved in mouse embryos by 10 days. 
Interestingly, this stage corresponds developmentally with the 
time of maximal sensitivity to teratogenic effects of congenital 
viral infections in human embryos. 
Gresser and coworkers have examined the effect of interferon 
on the growth of L1210 cells in vitro. Interferon inhibits the 
growth of L1210 cells; inhibition was directly proportional to 
interferon titer (Gresser, etal, 1970a, 1970b). Inhibition was 
evident at 24 hours, but was more pronounced at 48 hours. 
As interferon purification methods became more refined, it 
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became apparent that interferon itself was responsible for the 
anticellular effects observed (Gresser, etal, 1972a). 
Studies of macromolecular synthesis showed that growth 
inhibition of L1210 cells by interferon was accompanied by an 
inhibition of total RNA and protein svnthesis, and inhibition of 
polyribosome formation (Broutv-Boye, etal, 1973). No effect on 
the formation of free ribosomal subunits was observed. 
Examination of the cell cycle suggests that interferon 
decreases the doubling potential of each L1210 cell (Macieira- 
Coelho, etal, 1971). 
Study of interferon's antitumor activity showed noncycling 
tumor cells to be more sensitive to the antiproliferative effects 
of interferon than cells rapidly multiplying (Horoszewicz, etal, 
1979). Enhanced interferon activity might be seen when combined 
with drugs that impair cell-cycling activity, resulting in a 
population with a higher proportion of resting tumor cells. 
Several studies have shown interferon to be of particular benefit 
in combination with other antitumor drugs (Gresser, etal, 1978, 
Chirigos and Pearson, 1973). Chemotherapy and interferon in 
combination may be superior to either drug alone. 
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INTERFERON MEMBRANE RECEPTORS 
The presence o f a membrane-bound receptor svs tern for 
interferon has be en established for some time. It pi ays an 
impo r tant role in the expression of the antiviral ef f ec ts o f 
interferon . Bindi ng of interferon to specific cell sur face 
receptors is required for its antiviral action (Friedman, 1967). 
Evidence for the presence of an interferon receptor system 
comes from a variety of studies. 
Ouabain, which blocks membrane bound ATPase, inhibits the 
antiviral action of interferon without effect on its synthesis or 
release from the cell (Lebon, etal, 1975), implying a membrane- 
bound free energy requirement for interferon action. Similar 
inhibition occurs when interferon-producing cells are treated 
with specific antisera to interferon (Vengris, etal, 1975). This 
suggests interferon must interact with the external cell membrane 
is required for its antiviral action. 
Interferon covelently bound to Sepharose is capable of 
inducing an antiviral state (Ankel, etal, 1973). The Sepharose 
beads used had diameters several times those of the cells, which 
precluded internalization of the interferon-Sepharose construct. 
Increasing concentrations of interferon linked to a fixed number 
of beads yielded a sigmoidal dose-response curve with a sharp 
vertical slope. This curve suggests that a critical 
concentration of interferon molecules in contact with the 
receptors is needed to induce the antiviral state, which is thus 
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a cooperative process. 
Bourgeade and Chany (1976) postulated that cooperative 
activation could involve individual receptors or a number of 
them, and that the mobility of these receptors could be important 
in cellular response to interferon. Cvtochalasin B, colchicine, 
and vinblastine are known to disrupt microtubule and 
microfiliment systems, which have been associated with mobility 
of membrane bound proteins. When these substances were given 
simultaneously with interferon, they inhibited the antiviral 
response to interferon, while having no effect on RNA or protein 
synthesis. Integrity of the cytoskeletal components of the cell 
is necessary for activation. 
Interferon receptors contain both a glycoprotein and a 
ganglioside or gang 1 ioside-1ike component. An oligosaccharide 
moiety of this ganglioside or gang 1 ioside-1ike component is a 
critical feature for receptor function (Besancon, etal , 1976). 
Human KB-3 cells, unresponsive to interferon, have nearly absent 
levels of membrane gang 1iosides, especially GM2 and GM2; these 
gangliosides are present in high levels in membranes of sensitive 
mouse L cells. 
Binding and activation of antiviral mechanisms seem to be 
independent events. Binding of interferon to a ganglioside or 
ganglioside-1ike receptor is insufficient to establish an 
antiviral state. Human KB-3 cells, which are unresponsive to 
both mouse and human interferon, can bind both (Kohn, etal, 
1976) . 
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Cholera toxin and TSH also interact with cell surface 
receptors believed to contain a ganglioside as a functional 
component (Kohn, 1977). Recent experiments show that cholera 
toxin and TSH inhibit the antiviral action of interferon (Kohn, 
etal, 1976). This inhibition is related to action of these 
agents on the plasma membrane. 
Grollman and coworkers (1978) examined the effect of 
interferon on certain membrane characteristics, especially ion 
fluxes. Interferon causes an increase in the interior free 
calcium ion content of the cell by releasing calcium ions from a 
membrane-bound state. Interferon interaction with the membrane 
also induces a rapid efflux of protons from the cell and alter 
sodium and glycine uptake into the cell. A change in 
intracellular pH and an increase in net outside-to-inside Na + 
flux result. These both influence the electrical potential 
across the membrane. These membrane effects are specific, being 
absent in interferon-resistant cells, and are not induced by 
other agents binding the cell (cholera toxin or TSH). The 
relationship of these specific interferon-induced membrane 
changes and the establishment of the antiviral state is still 
unknown, and continues to be the subject of intense 
investigation. 
The antiviral activity of interferon can be blocked by 
inhibition of RNA or protein synthesis, suggesting that the 
antiviral state is dependant on expression of certain genetic 
information. 
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Bind i ng of inter f e ron to receptor s triggers the synthe si s of 
at least th ree protei ns wh ich act to prevent vir al re pi ic at ion . 
These pro te ins remain inac tive unt il viral infec tion o r ex po sure 
to doubl e- st r anded RNA occurs. This requi rement ma V be 
protective f spar ing host protein and nucleic ac id svn thes i s in 
the absenc e of viral i nfec t ion. 
The th ree prote ins known to be produced in re spon se to 
interferon include a pr o te in kinase, an ol igo nuc 1 eo tide 
svn thetase t and an endonuc lea se activa ted by that 
oligonucleotide. The oligonucleotide formed, known as 2-5A, is 
believed to mediate some of the antiviral and anticellular 
effects of interferon. 2-5A is discussed in greater detail in a 
later section of this thesis. 
INTERFERON RESISTANCE 
A ver v useful developmen t i n the study o f inter fer on systems 
ha s been the discovery of LI 210 cells resist an t to the anti viral 
and growth inhibito ry effects o f interferon. 
These inter fer on resista nt cells (LI 210 R) were fo und among 
wi Id or cloned populations o f interferon se ns i t ive LI 210 cells 
(L 1210 S) at a rate of 0.004 - 1 % (Gresser , e ta 1, 1974) It seems 
th at a sma 11 number of these cel Is are presen t in po pul at ion s of 
se ns: i t ive cells. Treatmen t of the parent popula t ion wi th 
in te i rferon selects for resistan t cells. Re si stan t c ells g row 
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exponentially in the presence of interferon, and an interferon- 
resistant cell population results. 
Fluctuation analysis tests show this interferon resistance 
results from spontaneous random change rather than induction from 
interferon (Gresser, etal , 1974). 
The mechanism of interferon resistance was investigated 
vigorously. No intracellular transfer of resistance could be 
demonstrated. L1210 S and L1210 R cells were cultivated together 
in suspension culture for six weeks, and had the same ratio of 
sensitive to resistant cells as when mixed initially. The 
generation times of both interferon sensitive and resistant cells 
were shown to be identical. Ultrasonic extracts of sensitive or 
resistant cells were unable to confer sensitivity or resistance 
when incubated with resistant or sensitive cells. No evidence 
was found to suggest the release of an interferon-inactivating 
factor by L1210 R cells. 
Interferon resistant cells are resistant to both the 
antiviral and anticellular effects of interferon. It is still 
unknown if the fundamental change is a gene mutation or a stable 
shift in phenotypic expression. Sensitivity to interferon 
appears to be the only difference detectable between these cell 
lines. L1210 S and L1210 R cells have the same generation time, 
the same chromosome pattern, the same colony-forming efficiency 
in agarose, and the same tumorogenicitv in DBA/2 mice. 
Interferon was recovered from extracts of interferon-treated 
L1210 S cells, but was not found in extracts of interferon- 
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treated L1210 R cells. The relevance of this finding to 
interferon resistance is unclear. However, other investigators 
(Stewart, etal , 1972) have demonstrated a correlation between 
recovery of interferon from various types of mouse cells and 
their sensitivity to the antiviral effects of interferon. 
Relative resistance to interferon has been noted in 
transformed cells. Broutv-Boye and colleagues (1979) transformed 
C3H/10T1/2 cells in vitro using x-irradiat ion or 
methvlcholanthrene treatment. The transformed cells were found 
to be 10 - 20 times less sensitive to the antiviral effects of 
interferon. A significant decrease in sensitivity to the 
anticellular effects of interferon was also noted. 
Earlier studies showed that in vitro transformation of cells 
by viruses (Bravilovskv, etal, 1969) or by chemical carcinogens 
(Rotem, etal, 1964) results in decreased sensitivity to 
interferon when compared to control, untransformed cells. 
Examination of sensitivity of several human cell lines to 
interferon showed that established aneuploid cell lines were much 
less sensitive to interferon than diploid cell lines (Moehring 
and Stinebring, 1973). However, other studies suggest that 
decreased sensitivity to interferon is not a characteristic of 
transformed cells. Freeman and colleagues (1970) examined normal 
rat embryo cells and found a wide variation in interferon 
sensitivity. They found no correlation between interferon 
sensitivity and transformation, leukemia virus infection or 
pretreatment with carcinogens. 
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Cell surface changes are common in transformed cells. 
Whether cell surface modification was associated with this 
particular transformation, and whether there is any role of cell 
surface changes in interferon sensitivity was not established. 
In vivo studies show interferon can protect mice inoculated 
with interferon resistant L1210 R tumor cells (Gresser , etal , 
1972), suggesting host-mediated inhibition of tumor growth may be 
triggered by interferon. Interferon may still be of value in vivo 
against tumor cells found to be resistant to its effects in 
vitro. 
Recent investigations with L1210 R cells have shown the 
ant iviral effe c ts o f interferon to be decreased in the presence 
o f fattv acid cycl oox ygenase inh ibito rs (Pottath il. etal, 1980). 
Sev eral anti- inflammatory dr ugs with kno wn fatty acid 
eye looxygenase in hib iting activ itv were used. The prevention of 
dev elopment of in ter feron antiv i ral protection cor related with 
the degree as we 1 1 a s the durat ion o f cyclooxvg enase inhibition 
for the vario us in hibitors tested . Other anti -inflammatory 
com pounds whic h 1 ack cyclooxygenase inhibiting ac t i vity did not 
af f ect antiv ira 1 protection by inter fer on. Exogenous 
pro stag 1 and ins d id not repl ace the need for functional 
cvc looxvgenase. In some c ases, add it ion o f exogenous 
pro stag land in ac tua llv dimini shed the antiv iral effect of 
interferon. 
LI210 R ce 11s we re subseque ntly found to lack a nv fatty acid 
eye looxvgenase ac t iv i ty (Chandra bose , etal, 198 1) . A diffusible 
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enzyme inhi bi tor could not 
1 ipo xygenase activ i t v wa s fo und 
sens itive and resist ant st rains 
o f fatty ac id cvc looxyg enase 
inte rferon se nsitivi ty is not ye 
Further resea rc h must be co 
the mechanism s of in ter fer on res 
be demonstrated. Fatty acid 
to be similar in both interferon 
of L1210 cells. The significance 
activity to the expression of 
t fully understood, 
nducted to completely understand 
istance. 
2-5A 
The mechanisms of interferon action have been the subject of 
intense investigation. One result of this research has been the 
isolation of a group of 2'-5' linked oligoadenvlic acid 
triphosphate inhibitors, known collectively as 2-5A. 2-5A is 
believed to play a crucial role in the induction of interferon 
action. 
2-5A inhibits cell-free protein synthesis. It is synthesized 
by an enzyme activated in interferon-treated cells in response to 
double-stranded RNA (Hovanessian, etal , 1977, Kerr and Brown, 
1978). This enzyme, 2-5A synthetase, utilizes ATP as its 
substrate. 
Treatment of mouse L cells with 2-5A resulted in inhibition 
of protein, RNA, and DNA synthesis. While these inhibitory 
effects are transitory at low 2-5A concentrations (<20 nM) , 
higher concentrations of 2-5A inhibit protein, RNA, and DNA 
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synthesis sufficiently to measurably affect cell growth. Protein 
svnthesis is noticeably inhibited after 30 minutes of incubation 
with 2-5A, before any effect on RNA synthesis is appreciated, 
suggesting independent mechanisms for protein and RNA inhibition 
by 2-5A. DNA synthesis is inhibited by 2-5A in a dose-dependent 
fashion 24 hours after treatment. 
Antiviral effects are also evident with 2-5A. Cells 
infected with vesicular stomatitis virus (VSV) show inhibition of 
viral RNA replication when treated with 2-5A (Hovanessian and 
Wood, 1980). Virus production is inhibited by 90-100% after 
treatment of infected cells with 10-100 nM of 2-5A. Antiviral 
activity seems to be mediated by a 2-5A dependent nuclease which 
degrades viral RNA. 
The 2-5A system may mediate the antiviral and anticellular 
effects of interferon. 
Interferon treatment enhances the levels of 2-5A synthetase 
activity. In the presence of double-stranded RNA and ATP, 2-5A 
is formed. 2-5A, in turn, activates a nuclease which degrades 
both polyadenylated and ribosomal RNA (Hovanessian, etal , 1979). 
Extracts from cells treated with 2-5A show enhanced nuclease 
activity in vitro when incubated with exogenous RNA (Williams, 
etal, 1979). This nuclease activity is transient, and the cell 
survives after the period when mRNA species are degraded. This 
provides an effective mechanism for eliminating undesired 
messages. 
The effect of 2-5A on intact cells is dependent on its 
41 

penetration into cells. Treatment of cells with hypertonic 
medium or by adsorption of 2-5A onto the cell membrane will 
facilitate penetration into cells. Several investigators have 
obtained good results with a calcium chloride coprecipitation 
technique (Hovanessian, etal, 1979). 
Preliminary studies indicate viral RNA synthesis can be 
reduced to background levels after 2-5A treatment. This suggests 
that the 2-5A activated nuclease may mediate the antiviral 
effects of interferon. 
Lengvel and coworkers have isolated 2-5A synthetase from 
mouse Ehrlich ascites tumor cells treated with mouse interferon 
(Dougherty, etal, 1980). They have studied the enzyme and its 
activity extensively, and have described the kinetics, 
stoichiometry, and equilibrium of the 2-5A synthetase reaction in 
detail (Samanta, etal, 1980). 
Kimchi and colleagues (1981) studied the antimitogenic 
effect of 2-5A on mouse spleen lymphocytes stimulated with 
Concanavalin A (ConA). Mitogens increased the intracellular 
levels of 2 '-phosphodiesterase, which degrades 2-5A. Ratios of 
2-5A synthetase to 2'-phosphodiesterase were examined. They 
propose a model of synthesis and degradation of 2-5A as a 
regulator of cell growth in the presence of interferon and 
mitogens. The ratio of 2'-phosphodiesterase to 2-5A synthetase 
was ten times higher in fast growing monkey kidnev cells than in 
serum-starved, quiescent cells arrested in GQ. Thev propose that 
the growth-dependent changes in 2'-phosphodiesterase activity 
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regulate the intracellular level of 2-5A, affecting cell 
proliferation. The model assumes constant production of 2-5A 
with rapid degradation by phosphodiesterase preventing 
accumulation and consequent growth inhibition. 
Cells of all vertebrates have a basal level of 2-5A 
synthetase activity (Stark, etal, 1979), which probably 
facilitates constant synthesis of 2-5A. 
Interferon specifically induces synthesis of 2-5A synthetase 
at the transcriptional level, increasing the enzyme level 10 to 
100-fold. Interferon treatment also increases 2'- 
phosphodiesterase levels 3 to 4-fold (Schmidt, etal, 1979). The 
precise mechanisms CO nt r o lling the v ar iation of 2 '- 
phosphod ie sterase leve Is wi th rate of cell g rowth ar e not clear . 
The rati o of synthetase to pho sphodieste rase remains much higher 
in inte r feron-treated ce 11s than in untr eated cells. Net 
svnthesi s of 2-5A resul ts in i nhibition of pr otein , RNA, and DNA 
svnthesi s. and ultima tel v ce 11 growth. Mi togens r everse this 
enzvmati c relationship 9 and phosphodieste ra se activ ity exceeds 
svntheta se activity. lea ding to net degrada tion of 2-5A The 
inhibito ry effects of 2 -5A d im inish, with acc elerated cell growth 
the final result. 
This model for the role of 2-5A in the control of cell 
proliferation is attractive, and further research is being 
conducted to substantiate it. 
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LIPOSOME ENCAPSULATION OF INTERFERON 
Liposomes have proven to be powerful tools, especially as 
carriers of biologically active agents. Their ability to prolong 
the half-life of entrapped species in vivo, to reduce the 
immunogenicity of entrapped species, and the developing ability 
to target liposomes to specific anatomic and intracellular sites 
make liposomes ideal carriers with enormous potential. The 
growing interest in interferon and its antiviral and anticellular 
effects make it an attractive candidate for liposome 
encapsulation. 
The advantages of liposome encapsulation seem well suited 
for interferon. Rapid in vivo clearance and degradation of 
interferon necessitate large and repeated doses of interferon. 
Encapsulation of interferon in liposomes would conceivably 
increase its in vivo activity. 
LaBonnadiere (1977) reported the association of mouse 
interferon with liposomes. Interferon was associated with 
liposomes composed of phosphatidylcholine, stearylamine or 
dicetyl phosphate, and cholesterol in a 7:2:1 molar ratio. Both 
sonicated and unsonicated liposomes were prepared. Sonication 
inactivated a large proportion of interferon activity, but the 
liposomes were associated with 9.6% (anionic) and 20% (cationic) 
of initial interferon activity. The unsonicated liposomes were 
associated with appreciable amounts of initial interferon 
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ac t i v itv : 18% was assoc ia ted wi th anion ic liposomes. 
Liposome encapsul a ted i nte r: feron pr eparations were treated 
wi th tr ypsin . Both a nionic and cat io ni c liposomes conta ined a 
fr act ion of inter fero n whic h wa: s sim ul taneouslv resist ant to 
tr yps in and still bio log ica lly active i n cell cu 1ture . This 
fr act ion represented 4 % of the total inte r fe ron ac tiv ity in 
an ion ic liposomes, and 5% of the total in cationic o nes. 
Triton X-100, a detergent, has been widely used to 
demonstrate the latency of various molecules in 1iposomes. Its 
action on 1iposome associated in terferon induced release of 
interferon from liposomes. The interferon activity so released 
was probably located internally. Multilamellar vesicles contain 
a large proportion of entrapped species in their internal aqueous 
spaces. 
Liposome encapsulated interferon was then used in its first 
known in vivo study. Liposome encapsulation enhanced the 
antiviral effect of interferon on mice infected with hepatitis 
virus (LaBonnadiere, 1978). This was presumed to be a result of 
the greater accumulation of the liposomes in the liver and the 
spleen. 
Anderson and colleagues (1981) successfully demonstrated 
entrapment of human leukocyte interferon in multilamellar 
liposomes. Liposomes were created from phosphatidylcholine, 
dicetyl phosphate, and cholesterol (7:2:1). The encapsulated 
interferon was resistant to inactivation by trypsin, which 
completely inactivated free interferon. A trapping efficiency of 
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11.0 + 1.9% is reported. Little evidence was found for 
significant electrostatic or hydrophobic interactions with the 
outer bilayer. Evidence suggested that liposomes capture 
interferon by passive entrapment. 
The association of interferon with liposomes probably 
modifies its intrinsic antiviral and anticellular activity, since 
liposome-cell interactions are the dominant interaction. Any 
molecules bound to the liposomes will be dependent on the 
liposome-cell interactions. 
Liposome association of interferon could increase its 
concentration in the vicinity of membrane bound receptors. Such 
association might allow a given amount of interferon to have a 
higher intrinsic activity. 
Liposome encapsulation of interferon could also allow 
detailed study of responses to interferon presented 
intracellularly. Many details of the membrane bound receptor 
system for interferon have been elucidated. However, it is not 
known if an intracellular receptor system for interferon exists. 
Other mechanisms might be available to allow interferon to 
express its antiviral and anticellular activity. The ability to 
introduce interferon directly into cells via liposomes will help 
elucidate the mechanism of action of interferon at steps distal 
to its receptor binding. 
Liposomes designed for fusion with cells would allow 
introduction of interferon into the cytoplasm. However, if 
endocytosis were significant, liposome encapsulated interferon 
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would be at g reater risk for degradation 
I f the endoc yt ic vacuo 1 e did not fuse 
contents could be either released slowly i 
secreted back into the ex tracel1 ular envir 
Liposome encapsula t ion of interf 
interest ing subjec t f o r i n vivo studies. 
inter fer on in Pi asma i s known to be 
encapsul a ted in te r fe ron should have a 
greater than the f ree spe c ies. The other 
encapsul at ion wou Id also be con ferred to 
investig ations • 
by lysosomal enzymes. 
with lysosomes, its 
nto the cytoplasm , or 
onment. 
eron would prove an 
The half-life of free 
very short. Liposome 
plasma half-life far 
advantages of liposome 
interferon for in vivo 
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EXPERIMENTS 
The experiments for this project were conducted in two 
phases. Phase I was conducted in the laboratory of Dr. Lois B. 
Epstein of the University of California San Francisco Cancer 
Research Institute, during the summer of 1980. Research could 
not be continued in Dr. Epstein's laboratory due to the need to 
return to New Haven. The remainder of experiments. Phase II, 
was conducted in the laboratory of Dr. Thomas R. Tritton of the 
Department of Pharmacology, Yale University School of Medicine, 
in close collaboration with Dr. Joseph R. Bertino, Department of 
Pharmacology and Medicine, and Dr. Peter Lengvel of the 
Department of Molecular Biology and Biophysics. 
DESCRIPTION 
Liposome Encapsulated Interferon and Free Interferon 
Free interferon is known to exert antiviral and anticellular 
effects. Gresser has studied the anticellular effects of 
interferon on the growth of L1210 cells in depth (Gresser, etal, 
1970b, 1970c, 1972a, Macieira-Coelho, 1971). It is of interest 
to see if and how liposome encapsulation affects the anticellular 
effects of interferon. 
L1210 cells were chosen for study because of extensive 
literature discussing the effect of interferon on their growth. 
They are easy to grow in suspension cultures and can be readily 
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counted with cell counting machines. 
Jansons (1978) studied the in vitro interaction of L1210 
cells with liposomes. Uptake of liposomes by cells was 
temperature dependent, and greater in young cultures than in 
stationary cultures. Uptake of positively charged liposomes by 
cells was significantly greater than that of either neutral or 
negatively charged vesicles. However, about one-half of the 
cel1-associated radioactivity seen with positively charged 
liposomes could be removed by cell surface treatment with 
trypsin, neuraminidase, or high-ionic-strength treatment, 
suggesting a significant degree of adsorption of liposomes to the 
cell surface. 
To maximize the cellular uptake of liposomes, a positive 
charge was given to the liposomes used (Phase II only). 
Liposomes were made using phosphatidylcholine, cholesterol, and 
stearylamine in a 4:3:1 molar ratio. Use of a charged liposome 
also enhances the capture rate of the entrapped species. 
Unsonicated multilamellar liposomes were used to 
encapsulate interferon. This type of vesicle is associated with 
an increased rate of entrapment. Experience with this vesicle in 
encapsulation of interferon (LaBonnadiere, 1977, Anderson, etal, 
1981) also made its use desirable. 
Initially, both cell growth and DNA synthesis were to be 
3 
measured, the latter by examining the incorporation of H- 
thymidine. However, Brouty-Boye and Tovey (1978) found that, 
3 
although interferon reduced H-thymidine uptake, the uptake of 
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3 . 3 H-deoxyadenosine and H-deoxy-D-glucose was not inhibited. They 
3 
conclude that reduced H-thymidine incorporation does not reflect 
a decrease in DNA synthesis, but rather a change in exogenous 
nucleoside utilization. Accordingly, measurement of DNA 
3 
synthesis by H-thymidine incorporation was not pursued. 
Liposome Encapsulated Interferon and Interferon Resistance 
Interferon resistant L1210 cells (L1210 R) were discovered 
and intensely studied by Gresser (1974). The actual mechanisms 
of interferon resistance have remained elusive. Though 
deficiency in the ganglioside content of interferon membrane 
receptors (Besancon, etal , 1976) and lack of fatty acid 
cyclooxygenase activity (Chandrabose, 1981) are differences 
identified in interferon resistant cells, their precise role in 
interferon resistance is unknown. The fundamental differences 
between sensitive and resistant cells are yet undefined. 
If interferon acts through a membrane bound receptor system, 
this system seems an appropriate place to search for differences 
between interferon sensitive and resistant cells. Differences in 
the ganglioside content of receptors have been noted (Besancon, 
etal , 1976). 
Liposome encapsulation of drugs has been used to overcome 
drug resistance. Papahadjopoulos and colleagues (1976) used 
liposomes to introduce actinomycin D into resistant tumor cells. 
Drug resistance in those cells was due to a decreased membrane 
permeability to the drug, with reduced ability to incorporate 
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actinomvcin D intracel1ularly. Liposome encapsulation allowed 
the drug to be introduced intracellularly, with marked inhibition 
of RNA synthesis and cell growth at concentrations that had 
little or no effect extracellularly. Liposome encapsulation was 
clearly able to overcome drug resistance due to decreased 
membrane permeability. 
Beca use the precise mecha nisms of resistance to interferon 
in LI 210 R cells are not known , the success of liposome 
encapsula tion of i nte r fe ron in overcom ing in terferon resistance 
ca nnot be pr edicted Ho wever , liposome enc apsulated interferon 
CO uld be a useful tool i n stud ying the mecha nism of interferon 
re sistanc e in these cells • 
Li posome Encapsulat ion of 2-5A 
The oligonucl eotide 2-5A, believ ed to be a med iator of the 
an tiviral and an ticel1 ular effects of inte r fe r on, cannot 
pe netrate intact plasma memb ranes. It exerts its effects 
in tracell ularly, so that entry into the cell is essen tial for its 
ac tivity. Entry o f 2-5A intracellular ly has been fa cilitated by 
pe rmeabil izing cel Is in hypertonic med ium, and with a calcium 
ph ospha te coprecipi tat ion techn ique (Ho vaness ian, eta 1, 1979). 
Sine e liposome s have been employed successfully to introduce 
a var ie ty of agents into cells, inc 1uding nucleotides 
(Papahadjopoulos, etal , 1974), it is reasonable to attempt to use 
liposomes to facilitate entry of 2-5A into cells, allowing 
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expression of its anticellular effects. 
Preliminary experiments were conducted to estimate the 
encapsulation rate of 2-5A. Since 2-5 A is expensive and 
difficult to obtain, ^H-ATP was used to estimate encapsulation 
rate because of similarity in structure to the olig 
Its relatively low cost and ready availability were 
favoring its use in estimation of 2-5A encapsulation 
was felt that 2-5A would exhibit liposome encapsulati 
similar to that of ^H-ATP. An encapsulation rate 
sonicated liposomes was estimated. 
Study of permeabi1ized cells was considered, 
liposome encapsulation of 2-5A with previously emplo 
of introducing 2-5A into cells. However, such compar 
pursued. If liposome encapsulation successfully int 
into cells, a decrease in the growth rate of 
presumably reflect the intracellular action of 2-5A. 
MATERIALS AND METHODS 
Phase I (UCSF): 
Interferon 
Pur ified mouse interferon was ki ndly provided by Dr . Kurt 
Paucker. Interferon was added to cell cultures at final 
concentrations of 0, 10, 30, 100, 300, and 1000 u/ml. 
onucleotide. 
also factors 
rate. It 
on behavior 
o f 1.6% in 
to compare 
yed methods 
i son was not 
reduces 2-5A 
cell s would 
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Cells 
L1210 cells were obtained from UCSF Cell Culture Facility 
frozen stock. Cell were grown in Dulbecco's modified Eagle's 
minimal essential medium supplemented with 10% heat-inactivated 
horse serum (Gibco), with 1% penicillin/streptomycin at 37' C in 
a 5% C02 humidified atmosphere. Experiments were conducted in 
plastic microwell dishes (Falcon). Cells were counted with a 
hemocytometer using the Trypan blue dye exclusion test for cell 
viability. 
Cell concentrations were measured after 48 hours of 
incubation, as anticellular effects of interferon are more 
pronounced at this time (Gresser, etal, 1970b). 
L1210 S and L1210 R cells were kindly provided by Dr. Ion 
Gresser. However, an unfortunate mycoplasma contamination 
precluded meaningful studies of these cells during Phase I. 
Liposomes 
Liposomes were prepared by the reverse evaporation phase 
(REV) method (Szoka and Papahadjopoulos, 1978) using 
phosphatidylglycerol and cholesterol in a 1:1 molar ratio. 
Interferon for liposome encapsulation was added to the lipid 
mixture in a concentration of 25,000 u/ml in TES/Histidine/NaCl 
buffer pH 7.4. Separation of free from encapsulated interferon 
was achieved by centrifugation in a Ficol1-Hypaque gradient. 
The concentration of liposome encapsulated interferon is 
reported as the estimated interferon concentration of the 
preparation. This was estimated by preliminary assay of liposome 
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encapsulated interferon activity by a virus plaque reduction 
method (Epstein, 
reported as th 
added to cell 
empty liposome 
concentration o 
preparation. 
Phase II (Yale): 
Interferon 
Purified mo 
Lengyel. Inter 
of 0, 5, 50, and 
Cells 
LI210 S and 
Lengve 1 . Four 
interferon sensi 
These lines we 
effects of i 
sensitivities 
laboratory of Dr 
Cells were 
heat-inactivated 
humidified atmos 
Cells were 
1976). The concentration of empty 
e dilution of the original liposome 
cultures. The lipid concentration 
preparation is equivalent to 
f the 1000 u/ml liposome encapsulated 
1iposomes 
pr eparat 
o f the 
the 1 i 
inter fe 
is 
ion 
1: 1 
pid 
ron 
use interferon was kindly provided 
feron was added to cells at final 
500 u/ml. 
by Dr. Peter 
concentrations 
L1210 R cells we re 
cell lines were ma 
five, and RF 3 and 
re assayed for sens 
nterferon, and 
were confirmed. 
. LeBleu. 
grown in Fischer's 
horse serum (Gi 
phere . 
counted on a Coulte 
kindly provided by Dr. Peter 
intained: RF 21 and SWA were 
RMI were inte r fe ron resistant. 
itivity to the an ticellular 
the ir reported inter feron 
Cells or iginated from the 
mediurn supplemented wi th 10% 
bco) at 37' C in a 5% C02 
r Counter . 
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2-5A 
Purified 2-5A (oligonucleotide of composition pppA(2,p5,A) 
was kindly provided by Dr. Peter Lengvel. 
n 
Liposomes 
Liposomes were prepared from phosphatidylcholine, 
cholesterol (both from Sigma Pharmaceuticals) and stearylamine 
(ICN K&K Laboratories) in a 4:3:1 molar ratio. Lipids were 
dissolved in chloroform and dried to a thin film under nitrogen. 
Purified mouse interferon, 2-5A or control buffer was added to 
the lipid film. Mechanical agitation (5 minutes on a Vortex 
mixer) was then applied, resulting in the formation of 
multilamellar vesicles. 
Sonicated unilamellar liposomes were prepared for 
encapsulation of 2-5A. After mechanical agitation, as described 
above, the liposome preparation was sonicated for 2 hours in a 
bath type sonicator (Laboratory Supplies Co., Inc.). 
Separation of free from encapsulated species was achieved by 
passing the mixture through Sephadex G-50 in a 1.5 x 25 cm BioRad 
column. Fractions were measured and collected by an LKB fraction 
collector. The elution profile of liposomes was determined by 
14 producing 'C-phosphatidvlcholine:cholesterol:stearylamine 
(4:3:1) liposomes and measuring radioactivity of sequential 
fractions. 
The liposome preparation was added to cells at a 
concentration of 0.2 mg lipid per million cells. 1:10 and 1:100 
dilutions of the liposome preparation were also added to cells. 
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The concentration of interferon 
preparation was estimated to be 500 
rates of interferon in multilamel 
Ande r son and colleagues (1981) • 
1 ipo some encapsulated interfere on, 
cone entr a t ions of 50 and 5 u/ml, we r 
The enc apsulation rate of 
enca psul a ting 3 . 14 H-ATP in C -pho 
stea rylam ine liposomes (4:3:1) and 
sequential fractions. Based on an 
sonicated unilamellar vesicles, the 
liposome encapsulated 2-5A preparat 
nM. 
in the liposome encapsulated 
u/ml, based on encapsulation 
lar vesicles as reported by 
1:10 and 1:100 dilutions of 
with estimated interferon 
e also incubated with cells. 
2-5A was estimated by 
sphatidylcholine:cholesterol: 
measuring radioactivity of 
encapsulation rate of 1.6% in 
concentration of 2-5A in the 
ion was estimated to be 100 
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DATA 
Phase I (UCSF) 
Table 1 
Effect of Liposome Encapsulation of Interferon on the Growth of 
LI210 Cells 
(First Trial) 
6 (cell concentration x 10 cells/ml) 
Cell concentration at 0 hrs, 0.232 
Cond it ion Cell Concentration 
at 48 hours 
% contri 
Control 2.92 5 100.00 
Emptv Liposomes 1:1 2.797 95.62 
1:3.33 2.770 94.70 
1: 10 2.805 95.90 
1: 33.33 3. 040 103.93 
1: 100 2.780 95.04 
Free Interferon 1000 u/ml 1.485 50.77 
300 u/ml 1.668 57.03 
100 u/ml 1.948 66.60 
30 u/ml 2. 573 87.97 
10 u/ml 2. 335 79.83 
Liposome 1000 u/ml 2.600 88.89 
Encapsulated 300 u/ml 2.678 91.56 
Interferon 100 u/ml 2.913 99. 59 
30 u/ml 2.775 94.87 
10 u/ml 2.018 68.99 
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Table 2 
Effect of Liposome Encapsulated Interferon on the Growth of 
LI210 Cells 
(Second Trial) 
10^ cells/ml) 
0 hours 0.282 
Cell Concentration % control 
at 48 hours 
Control 3.090 100.00 
Empty Liposomes 1:1 2. 170 70.23 
1:3.33 2.955 95.63 
1: 10 2.450 79.29 
1:33.33 2.695 87.22 
1: 100 3. 278 106.08 
Free Interferon 1000 u/ml 1.660 53.72 
300 u/ml 1.962 63. 50 
100 u/ml 2.120 68.61 
30 u/ml 2. 582 83. 56 
10 u/ml 2.250 72.82 
Liposome 1000 u/ml 0.760 24.60 
Encapsulated 300 u/ml 2.038 65.95 
Interferon 100 u/ml 2.498 80.84 
30 u/ml 2.628 85.05 
10 u/ml 2.065 66.88 
(cell concentration x 
Cell Concentration at 
Condition 
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Phase II (Yale) 
Table 3 
Effect of Liposome Encapsulated Interferon on the Growth 
of L1210 S and L1210 R cells. 
L1210 Sensitive Cells 
(control - cell concentration x 10° cells/ml) 
(other conditions - % of control concentration) 
Condit ion 0 hr 24 hr 48 hr 72 hr 
Control 0. 566 1. 19 4. 51 8.45 
Empty Liposomes 
1:1 
1: 10 
1: 100 
100.00 
100.00 
100.00 
99.16 
97.48 
93. 28 
99.33 
97.12 
96.01 
107.34 
106.27 
105.44 
Free Interferon 
500 u/ml 
50 u/ml 
5 u/ml 
100.00 
100.00 
100.00 
87.39 
91.60 
96.64 
63. 19 
76. 50 
100.67 
73.49 
91.36 
100.71 
Liposome Encapsulated 
Interferon 
1:1 100.00 
1:10 100.00 
1:100 100.00 
96.64 
100.84 
96.64 
88.69 
96.67 
94.01 
97.28 
102.49 
96.57 
L1210 Resistant Cells 
(control - cell concentration x 10 cells/ml) 
(other conditions - % of control concentration) 
Cond it ion 0 hr 24 hr 48 hr 72 hr 
Control 0.485 1.38 4.68 8.17 
Emptv Liposomes 
' 1: 1 
1: 10 
1: 100 
100.00 
100.00 
100.00 
97.10 
96.38 
95.65 
102.35 
105.34 
104.27 
87.88 
92.04 
87.39 
Free Interferon 
500 u/ml 
50 u/ml 
5 u/ml 
100.00 
100.00 
100.00 
96.38 
92.75 
100.72 
104.70 
105.56 
104.27 
91.80 
92.17 
88.49 
Liposome Encapsulated 
Interferon 
1:1 100.00 
1:10 100.00 
1:100 100.00 
92.03 
94.93 
95.65 
102.35 
107.48 
103.21 
82.50 
85.68 
84.58 
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Table 4 
Effect of Liposome Encapsulated Interferon on Sensitive and 
Resistant L1210 Cells 
RF3 - Resistant 
(cell concentration x 10 cells/ml) 
(% of control concentration indicated in parentheses) 
Condition 0 hr 24 hr 48 hr 72 hr 
Control 1. 16 3.776 7.835 7. 537 
Empty Liposomes 1. 16 
(100.00) 
3.460 
(91.63) 
7.677 
(97.98) 
7. 377 
(97.35) 
Liposome 
Encapsulated 
Interferon 
1. 16 
(100.00) 
1.442 
(38.19) 
2.732 
(34.87) 
8. 125 
(107.80) 
RF 21 Cells - Sensitive 
(cell concentration x 10D cells/ml) 
(% of control concentration indicated in parentheses) 
Condition 0 hr 24 hr 48 hr 72 hr 
Control 0.493 1.086 2.745 5.726 
Empty Liposomes 0.493 
(100.00) 
1.027 
(97.34) 
2.370 
(86.34) 
7.671 
(133.97) 
Liposome 
Encapsulated 
Inter feron 
0.493 
(100.00) 
0. 534 
(49.17) 
0.778 
(28.34) 
2.020 
(35.28) 
RMI Cells - Resistant s 
(cell concentration x 103 cells/ml) 
(% of control concentration indicated in parentheses) 
Condition 0 hr 24 hr 48 hr 72 hr 
Control 0.614 1.795 6.037 8.293 
Empty Liposomes 0.614 
(100.00) 
1.756 
(97.83) 
5.868 
(97.20) 
8.889 
(107.19) 
Liposome 
Encapsulated 
Interferon 
0.614 
(100.00) 
0.832 
(46.35) 
1.684 
(27.89) 
6.741 
(81.29) 
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Table 5 
Effect of Liposome Encapsulated 2-5A on the Growth of 
LI210 S and L1210 R Cells 
L1210 Sensitive Cells 
(cell concentration x 10') cells/ml) 
(% of control concentration indicated in parentheses) 
Condition 0 hr 24 hr 48 hr 72 hr 
Control 0. 514 1.213 5. 145 8. 555 
Free 2-5A (lOQnM) 0. 514 
(100.00) 
1.214 
(100.08) 
5. 080 
(98.74) 
9. 499 
(111.03) 
Empty Liposomes 0. 514 
(100.00) 
1. 193 
(98.35) 
5. 046 
(98.08) 
8.846 
(103.40) 
Liposome 
Encapsulated 2-5A 
0.514 
(100.00) 
1.083 
(89.28) 
4. 343 
(84.41) 
7.937 
(92.78) 
L1210 Resistant Cells ^ 
(cell concentration x lO3 cells/ml) 
(% of control concentration indicated in parentheses) 
Condition 
Control 0.498 1.243 4.643 8.063 
Free 2-5A (lOOnM) 0.498 
(100.00) 
1.226 
(98.63) 
4. 360 
(93.90) 
7. 343 
(91.07) 
Empty Liposomes 0. 498 
(100.00) 
1. 179 
(94.85) 
4.244 
(91.41) 
7. 556 
(93.71) 
Liposome 
Encapsulated 2-5A 
0.498 
(100.00) 
1.091 
(87.77) 
3.841 
(82.73) 
7. 669 
(95.11) 
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RESULTS 
LIPOSOME ENCAPSULATION OF INTERFERON 
1. Comparison with Free Interferon 
Phase I (UCSF) 
The results of the first trial with liposome encapsulated 
interferon are summarized in Table 1. Free interferon showed 
dose-dependent growth inhibition of L1210 cells, with growth 
inhibition to 50.77% of control cell concentration seen with 1000 
u/ml at 48 hours. Empty liposomes showed no effect on cell 
growth at all concentrations. Liposome encapsulated interferon 
did not demonstrate appreciable effect on cell growth. Liposome 
encapsulated interferon at 10 u/ml did exhibit growth inhibition 
(69% of control at 48 hours). However, such inhibition was not 
consistent with the low estimated concentration of interferon. 
Attempts to replicate this finding in were complicated as 
described below. 
Table 2 displays results from a second trial of liposome 
encapsulated interferon. Free interferon again demonstrated a 
dose-dependant growth inhibitory effect, with cell concentration 
53.72% of control at 1000 u/ml. Surprisingly, both empty 
liposomes and liposome encapsulated interferon showed significant 
growth inhibition at their higher concentrations. Empty 
liposomes reduced cell concentration to 70.23% of control in its 
highest concentration. While marked growth inhibition was seen 
with the liposome encapsulated interferon (24.60% of control 
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concentration at 1000 u/ml, 65.95% of control concentration at 
300 u/ml), these results are not valid. Inhibition by empty 
liposomes had not been seen previously, nor was it expected with 
the amount of lipid per cell used. The liposome preparation used 
demonstrated cytotoxic effects in the absence of interferon 
(Table 2). These findings significantly complicated data 
analysis, and these results were therefore not accepted as truly 
representing the effects of liposome encapsulated interferon. 
Experiments did not indicate that liposome encapsulation 
significantly increased the anticellular effect of interferon. 
However, time limitations at Dr. Epstein's laboratory precluded 
adequate resolution of difficulties encountered in experiments 
examining the anticellular effects of liposome encapsulated 
interferon. Research was therefore continued in Dr. Tritton's 
laboratory at Yale. 
Phase II (Yale) 
Comparisons between free and liposome encapsulated 
interferon were repeated at Yale. However, several experimental 
conditions were necessarily changed as a result of working in 
different laboratories. 
The sources of interferon and cells were different. The 
purity of currently available mouse interferon, and the low 
phenotypic variability of cultured L1210 cells made changes in 
these experimental conditions of minimal concern. 
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The most significant change between phases I and II was in 
liposome preparation. In Phase I, neutral liposomes of 
phosphatidylglycerol and cholesterol (1:1) were prepared by the 
reverse evaporation phase (REV) method. While continued use of 
these vesicles would have been desirable, prospects for their 
creation at Yale were not favorable, since neither the proper 
experience nor equipment were available. At Yale, liposomes were 
prepared by the standard method of mechanical agitation of the 
phospholipid film with an aqueous phase. Unsonicated, 
multilamellar vesicles were employed for the encapsulation of 
interferon since the capture rate is higher with this type of 
vesicle. Additionally, several investigators had reported their 
experience with the encapsulation of interferon in unsonicated 
multilamellar vesicles (Anderson, 1981, LaBonnadiere, 1977). 
Liposome encapsulated interferon demonstrated curiously variable 
effects on cell growth as shown in Tables 3 and 4. While 
preparations of liposome encapsulated interferon used in Table 3 
had no growth inhibitory effect, preparations used in Table 4 
showed significant anticellular effects, evident at 24 hours, but 
more pronounced at 48 hours. 
None of the preparations in phase II showed toxicity of 
empty liposomes, which had complicated an earlier experiment in 
phase I (Table 2). The growth inhibition seen in table 4 was due 
to the inhibitory effects of interferon. Differences in the 
interferon activity of the various preparations clearly existed. 
The availability of a quick, reliable assay for interferon 
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activity of the liposome encapsulated interferon preparations 
would have been desirable, and would help explain the differing 
results obtained with the different preparations. Such an assay 
was, unfortunately, not available to this laboratory. 
There are some aspects of liposome preparation which might 
have affected interferon activity. These factors may account for 
the variation in interferon activity observed with different 
liposome encapsulated interferon preparations. 
1) Incomplete drying of lipid mixture before introduction 
of the interferon mixture could have left residual chloroform in 
the preparation vessel, which could have denatured the 
interferon. 
2) Mechanical agitation is known to inactivate interferon. 
(Edy, etal, 1974) Thi s step of preparation t however, was 
CO nstant for all 1ipo some preparat ions. 
3) The chromatog ra ph ic gel may have been con tam: mated by 
substance s a ble to decrea se the ac tivity of inter fer on. Attempts 
we re made to m in im i ze sue h contami nation by stori ng the column in 
so dium az ide when not in us e . 
It is d i f ficul t to d etermin e the precise rea son for the 
d i fferenc es in inte r f er on activi ty observed. Fut ure resea rch 
ef forts in this area mus t resolve such differenc es, and str ive 
fo r unifo rm i ty. 
2. Ef f ec t o n Interfe ron Re sistant Cells 
Table 3 illustrates the effect of liposome encapsulated 
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interferon on the growth of L1210 sensitive and resistant cells. 
Results with this liposome encapsulated interferon preparation 
show no significant effect of liposome encapsulated interferon on 
the growth of L1210 R cells. 
The experiments summarized in Table 4 are most interesting. 
The effect of empty liposomes and of liposomes containing 
interferon were examined in three cell lines, two resistant and 
one sensitive to the effects of interferon. In all three cell 
lines, empty liposomes had very little effect on cell growth. 
Liposomes containing interferon had marked inhibitory 
effects on cell growth with all three cell lines, two of which 
were interferon resistant lines. The effect was evident at 24 
hours, but was greatest after 48 hours of incubation. Inhibition 
of sensitive cells remained significant at 72 hours (35.28% of 
control). However, the inhibitory effect on interferon resistant 
cells was markedly decreased by 72 hours of incubation, with the 
two resistant cell lines showing cell concentrations 107.80% and 
81.29% of control. 
This difference in effect at 72 hours may be related to the 
sensitivity or resistance of the cells to the anticellular 
effects of free interferon. Decreased effect of liposome 
encapsulated interferon after 72 hours of incubation could be 
expected if leakage or dissociation of interferon from liposomes, 
or breakdown of the liposomes themselves was significant. 
However, this does not explain the observed differential 
sensitivity between interferon sensitive and resistant cells. 
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L1210 cells resistant to the anticellular effects of free 
interferon exhibit growth inhibition when incubated with liposome 
encapsulated interferon. Anticellular effects are evident at 24 
hours, but are more pronounced after 48 hours of incubation. 
These effects are decreased after 72 hours of incubation. 
The mechanism of interferon resistance in L1210 R cells is 
unknown. Liposome encapsulation of interferon allowed expression 
of anticellular activity in cells resistant to free interferon. 
Liposome encapsulation may have altered the nature of interferon 
interaction with its membrane receptor, allowing expression of 
anticellular activity in normally resistant cells. 
Alternatively, liposome encapsulated interferon may have 
gained access directly into the intracellular environment. 
Endocytosis and fusion would allow liposome encapsulated 
interferon to cross the plasma membrane. The anticellular 
activity seen in resistant cells may have resulted from 
interferon exerting its anticellular activity through an 
intracellular mechanism. If liposome encapsulated interferon 
exerted its effects intracellularlv in L1210 R cells, its action 
was independent of the membrane receptor system. This raises new 
questions about alternative mechanisms of interferon action. 
Concurrent incubations with interferon were not conducted 
during the experiments summarized in Table 4. Such incubations 
would have allowed direct comparison of an effective preparation 
of liposome encapsulated interferon with free interferon. 
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LIPOSOME ENCAPSULATION OF 2-5A 
Neither free 2-5A (100 nM) nor liposome encapsulated 2-5A 
(estimated concentration 100 nM) were able to inhibit the growth 
of L1210 S or L1210 R cells. Hovanessian and Wood (1980) 
demonstrated significant inhibition of cell growth at 2-5A 
concentrations of >10 nM, using a modified calcium phosphate 
coprecipitation technique to allow 2-5A access to the internal 
cellular environment. 
These experiments indicate that liposome encapsulation of 2- 
5A cannot facilitate its entry into cells sufficiently to produce 
measurable growth inhibition. 
The failure of liposome encapsulated 2-5A to significantly 
inhibit cell growth could reflect several factors. 1) The 
estimation of encapsulation rate could have been erroneous. ^H- 
ATP and 2-5A might exhibit significantly different behaviors when 
incorporated into liposomes. The amount of 2-5A actually 
encapsulated could have been much lower than expected. 2) 
Leakage of 2-5A out of liposomes might have occurred at a rate 
high enough to decrease the amount available for transfer into 
cells. 3) Inactivation of 2-5A might have occurred during some 
phase of liposome preparation. Nucleic acids have been 
inactivated by sonication during liposome preparation (Poste, 
etal , 1976). As with liposome encapsulated interferon, the 
availability of an assay for 2-5A activity would have been most 
valuable. 4) Liposome-cell interaction could have involved 
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mechanisms (e.g. stable adsorption) which might not have allowed 
maximal internalization of liposomes and their contents. 5) 
Endocytosis of liposomes could have occurred, with 
lysosomal fusion and subsequent enzymatic of degrada 
by nucleases before its growth inhibitory actio 
manifested . 
significant 
tion of 2-5A 
n could be 
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DIRECTIONS FOR FUTURE INVESTIGATION 
Review of this project reveals several areas of concern for 
future research. 
A major obstacle throughout the course of this project was 
the lack of a method for precisely determining the amount of 
interferon associated with liposomes. Constraints of facilities 
and time precluded development of methods for accurate 
determination of liposome associated interferon activity. 
Accurate determinations of encapsulation rates based on 
interferon activity will allow more meaningful comparisons 
between free and liposome encapsulated interferon. This is surely 
one of the most important tasks to be addressed in future 
investigations using liposome encapsulated interferon. 
Assays of interferon presently available rely on 
measurements of its biological activity through the methods 
described earlier. Development of interferon assays which 
require less time for accurate determination of the presence of 
interferon would certainly have effects on interferon research. 
Radiolabelling of interferon, or the use of anti-interferon 
antibodies in assays (e.g. radioimmunoassay) might prove useful. 
However, while such assays might yield more rapid quantitative 
measurements of interferon, they would offer no indication of its 
biological activity. 
Liposome encapsulated interferon could also be used to 
explore other areas of interferon biology. There are many areas 
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of future research in which liposome encapsulated interferon 
could play a central role. 
The action of intracellular interferon is not known. 
Liposome encapsulated interferon could be used to examine such 
action, and to explore possible intracellular mechanisms for 
interferon activity that exist independant of the membrane 
receptor system. 
Species specificity of interferon is governed by membrane 
receptors (Bourgeade, 1974). Liposome encapsulation of 
interferon might overcome species specificity through 
circumvention of the membrane receptor system. 
The mechanisms of interferon resistance are unknown. 
Liposome encapsulated interferon could be used to better 
understand these mechanisms. Results of this project indicate 
that cells resistant to the anticellular effects of free 
interferon will exhibit growth inhibition when incubated with 
liposome encapsulated interferon. Perhaps liposome encapsulation 
allowed interferon to bypass defective interferon receptors. 
Such results are only the first step in a long series of 
investigations needed to reveal the mechanisms of interferon 
resistance . 
In vivo studies using interferon would benefit greatly by 
use of liposome encapsulated interferon. The many advantages of 
liposome encapsulation would be extended to interferon. Plasma 
half-life of free interferon, known to be short, would be greatly 
extended. Immunogenicitv of interferon could be reduced. 
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Targeting of interfe 
could be achieved 
LaBonnadiere (1978) 
liposome associated 
effect on mice infec 
in vivo studies ex 
encapsulated interfe 
clear the full poten 
ron to specific organs or intracellular sites 
through the targeting methods described, 
conducted the first known in vivo study using 
interferon, and found an enhanced antiviral 
ted with hepatitis virus. There are no known 
amining the anticellular effects of liposome 
ron. In vivo experiments will certainly make 
tial of liposome encapsulated interferon. 
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APPENDIX A - Lipid Membrane Fluidity 
from Pagano and Weinstein, 1978 
A 6 
* 
I Hi. 7. Schematic representation of mofeculjr orientation in phospholipid bi!a*crs hclo.v 
(A) and above IB) the phase trairsiiwn The head group- ef the phospholipid molecules 
arranged as a biluyer a^c shown by the open circles, aad the fatty acyl chains by solid lines 
Below the phase transition, the motion of the aeyi chains is inhibited as indicated by the 
straight lines Above the phase transition (B) the acyi chains have greater motional free jom, 
and this is indicated h> the curved lines. The effect of the introduction of cholesterol into a 
fluid hilayer is sbowr, in (C) Cholesterol *> represented hy a small dark circle (hydroxyl), a 
larger circular area t'.hc four-ring sicroid skrhetor) aac a curved Iw»e f hydrocarbon tall). The 
dimensions for the thickness of the btliyrr m(A) and(Bi refer to dipalmitoy) phosphatidyl¬ 
choline bilayexs ar*J in (Cl to a pfc-%pbai*J>lcS>olinc-chokacroi tilaycr. Full references to :hr 
Table 1 Properties of phospholipids used m hposomes 
Abbrevi¬ 
ation Charge 
Tc 
< c) 
eKPC 0 -15 to 
DO PC 0 -22 
DLPC 0 -0 
DM PC 0 +23 
DPPC 0 +41 
DSPC 0 + 5? 
D1PC 0 • 
brain SM 0 432 
egt PE D 
DM PE 0 + 43 
DM 1*0 - +23 
DMPA — +52 
brain PS — + 5 
DCF — 
SA + 
— 
~43 
0 in w 
lipid type 
Single Components 
Egg phosphatidylcholine 
Diolecyl phosphatidylcholine (C1S |) 
Dilauryl phnsphatidylcholine fCn«) 
Dimynstoyl phosphatidylchnl.na (Ci«c> 
Dipalmitoyl phosphatidylcholine (C,to) 
Distearo)! phosphatidylcholine (C|k.0) 
Dnsostearoyl phosphatidylcholine 
Bovine brain sphingomyelin 
Ejg phnsphalidylcthanolaminc 
Dimynstoyl phosphatidykthamEasnine (C,«o> 
Dimynstoyl pbosphatidylgljcerol 
Dimynstoyl phosphatidic acid. pH 6 
Boviite brain phfKphatiJybennc 
Dicetyl phosphate 
St«f)Utnint (C |tx) 
Oxninm Mixtures 
PS/DSPC/DPI*C (14.5:4-5) 
DPt*C : cholesterol (II) 
• K* otacrv-1 ~r the tempers -JOm +75<C (W) l * prc^abl, <-VC 

APPENDIX B - Mechanisms of Liposome-Cell Interaction 
from Kimelberg and Mayhew, 1978 
EKDOCYTOtrS Of LIPOSOMES 
me arr*oe-*r. fey 
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MEMBRANE 
FIGURE 7. PtrtUHft reactions ktvtn ceils, Iposoma, 
and KWi cwppoacnn. Diagram shews porsbiiitic? for ex¬ 
change of lipid components, denoted as short fistt within the 
Kpid Ubiv membrane, directly with membrane after sorfaee 
adsorptios (I) o* Mirectly via seram plasm* proteins (Bpopro- 
ldnf)(2). (?). 
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APPENDIX C In vivo Behavior of Liposomes 
APPENDIX D 
from Time, 
fwtmat wt bjeud 'H-flwpketSpH jkt Cna 
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•fiejcnka 
Un 
35*p& 
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}4 14 
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1.1 14 
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- The First Clinical Trial of Interferon 
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